Under normal circumstances, GLP-1 performs several functions: it stimulates insulin release, suppresses glucagon secretion, slows gastric emptying, and signals satiety to the brain
If trials continue successfully, potential FDA approval could occur in late 2026 or early 2027
This is a cash-pay model, meaning no insurance involvement and no prior authorization delays
Some individuals use this combination with the aim of supporting physical performance or weight management, though clinical evidence supporting such benefits remains limited
doi: 10.1080/09513590.2020.1760820
Women using GLP1 drugs have described Ozempic vulva, including sagging, loss of vulvar fat pads, and discomfort with sitting or cycling